IOL Chemicals And Pharmaceuticals Ltd.
NSE: IOLCP · Healthcare
Sector
Healthcare
Size band
Small cap
Market cap
2,312cr
P/E
19.9
ROE
6.1%
Dividend yield
1%
No price is shown on this page, live or delayed. It records what management said on the earnings call, and the company’s filings.
Measured against
Peer set
Pharmaceuticals & Drugs · largest 12 of 82 measured at Q1 FY27 · financials via Screener| Company | Operating margin | Revenue growth |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 29.0% | 10.5% |
| Divi's Laboratories Ltd. | 41.0% | 27.8% |
| Torrent Pharmaceuticals Ltd. | 34.0% | 54.8% |
| Lupin Ltd. | 30.0% | 32.1% |
| Dr. Reddy's Laboratories Ltd. | 11.0% | −5.5% |
| Cipla Ltd. | 17.0% | 2.3% |
| Zydus Lifesciences Ltd. | 24.0% | 22.0% |
| Mankind Pharma Ltd. | 26.0% | 12.9% |
| Aurobindo Pharma Ltd. | 21.0% | 16.3% |
| Torrent Power Ltd. | 19.0% | 2.8% |
| Alkem Laboratories Ltd. | 20.0% | 10.9% |
| IOL Chemicals And Pharmaceuticals Ltd. | 14.0% | 37.0% |
What management said
9 statements on recordEarnings call · Q1 FY27 · 20 Aug 2026
- FY27 revenue growth→15% to 20% revenue growth· financial year 27
“For financial year 27, we remain confident of delivering 15% to 20% revenue growth with an EBITDA margin in the range of 14% to 15% and exports contributing approximately 25% to 30% of the revenue.”
- FY27 EBITDA margin→14% to 15%· financial year 27
“For financial year 27, we remain confident of delivering 15% to 20% revenue growth with an EBITDA margin in the range of 14% to 15% and exports contributing approximately 25% to 30% of the revenue.”
- FY27 export contribution→approximately 25% to 30% of the revenue· financial year 27
“For financial year 27, we remain confident of delivering 15% to 20% revenue growth with an EBITDA margin in the range of 14% to 15% and exports contributing approximately 25% to 30% of the revenue.”
- Annual capex→approximately INR200 crores every year· every year
“Jainam ji, we follow a capex of approximately INR200 crores every year, which is planned with a long term view to support sustainable growth.”
- Capex allocation→60% towards expansion and new product; 40% to infrastructure
“Out of total capex planned, 60% is directed towards expansion and new product. And the remaining 40% goes to infrastructure, improvements for better efficiencies and reduction in cost.”
- Paracetamol capacity utilisation→around 70%· by the end of this financial year
“And as of now we are operating at around 55% of enhanced capacity, which we expect, by the end of this financial year, will be reaching to around 70%.”
- FY28 topline growth and EBITDA margin plan→15% to 20% in top line and EBITDA to 15% to 17%· FY '28
“Definitely, we have a plan to grow about 15% to 20% in top line and EBITDA to 15% to 17% in '28 approximately.”
- Non-Ibuprofen contribution to API segment→around 50% to 55%· FY '29
“For FY '29 only after three to four years, we are expecting that non-Ibu segment will contribute around 50% to 55% of our API segment with good margin equivalent to the other Ibuprofen margins.”
- Triacetin revenue potential→Around INR120 crores per year· per year
“Hello? Around INR120 crores per year.”
Taken from management commentary on the company’s earnings call and quoted verbatim. These are statements of intent made by the company, not forecasts by Bharatstox, and nothing here records whether they were met.
On air
8 calls · outcomes not trackedRecorded as stated on air, with the analyst's SEBI registration status where it was given. Anchor calls carry no registration and are marked. Bharatstox does not make, endorse or repeat these calls, and none of them is our view.
| Channel & show | Aired | Stated target | Stated stop | Outcome |
|---|---|---|---|---|
| Zee BusinessZee Business · no registration attached | 7 Oct | +2.8% | -3.3% | still open |
| Zee BusinessZee Business · no registration attached | 7 Oct | +5.1% | -3.3% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 29 Sep | — | -2.6% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 29 Sep | — | -2.5% | still open |
| CNBC AwaazCNBC Awaax · no registration attached | 29 Sep | — | -2.0% | still open |
| Zee BusinessZee Business · no registration attached | 24 Sep | +4.1% | -1.3% | still open |
| Zee BusinessZee Business · no registration attached | 24 Sep | — | -5.1% | still open |
| Zee BusinessZee Business · no registration attached | 24 Sep | +4.4% | -1.0% | still open |
Shareholding
change across 4 filings| Category | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Change |
|---|---|---|---|---|---|
| Promoters | 62.3 | 57.5 | 52.6 | 52.6 | +9.7 |
| Foreign institutions | 4.9 | 1.7 | 2.1 | 2.3 | +2.6 |
| Domestic institutions | 0.4 | 0.0 | 0.0 | 0.0 | +0.4 |
| Retail & others | 32.4 | 40.8 | 45.3 | 45.1 | −12.7 |
As filed with the exchange for the periods ending Sep 25 to Jun 26.
Filings
latest 25 of 265- Certificate under SEBI (Depositories and Participants) Regulations, 20187 Oct 2026
- Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals25 Sept 2026
- Trading Window25 Sept 2026
- Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals23 Sept 2026
- EU-REACH Registration for Triacetin23 Sept 2026
- Analysts/Institutional Investor Meet/Con. Call Updates23 Sept 2026
- Analysts/Institutional Investor Meet/Con. Call Updates23 Sept 2026
- Schedule of Analyst/Institutional Investor Meeting23 Sept 2026
- Schedule of Analyst/Institutional Investor Meeting23 Sept 2026
- Dispatch of Reminder letter to Shareholders to Update KYC21 Sept 2026
- General Updates21 Sept 2026
- Analysts/Institutional Investor Meet/Con. Call Updates17 Sept 2026
- Transcript of Business Update Call with Investors and Analysts17 Sept 2026
- Audio Recording of Business Update Call with Investors and Analysts11 Sept 2026
- Analysts/Institutional Investor Meet/Con. Call Updates11 Sept 2026
- Analysts/Institutional Investor Meet/Con. Call Updates10 Sept 2026
- Business Update Conference Call to discuss the Company's recent business developments and strategic growth initiatives with investors and analysts10 Sept 2026
- General Updates9 Sept 2026
- Expansion of Ibuprofen Capacity, New CDMO Business for Pharmaceutical Formulation and Dedicated Specialty Chemicals Manufacturing Facility9 Sept 2026
- Shareholders meeting2 Sept 2026
- Voting Results and Scrutinizer''s Report2 Sept 2026
- Shareholders meeting2 Sept 2026
- Outcome of the AGM2 Sept 2026
- Analysts/Institutional Investor Meet/Con. Call Updates26 Aug 2026
- Schedule of Analyst/Institutional Investor Meeting26 Aug 2026
The 25 most recent of 265 filings we hold for IOLCP, back to January 2024. Every filing, by day.
Disclaimer
Guidance is quoted from management commentary on quarterly earnings calls; the words are the company's own and the targets are theirs, not ours. Peer comparisons use quarterly financials sourced from Screener, with every company measured at the same fiscal quarter; the peer set is companies sharing the same industry classification, and comparisons are descriptive, not a ranking or a view. Broadcast calls are reproduced as stated on air, attributed, with the analyst's SEBI registration status where given; they are not our calls and not our view. Filings are reproduced as companies filed them to the NSE and BSE; Bharatstox does not verify, endorse or comment on their contents. This page is for informational and educational purposes only and does not constitute investment advice, research, or a recommendation to buy or sell any security. Investing in securities markets is subject to market risks. Read all related documents carefully before investing.